Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
101.00
(
-0.53%
)
Bitcoin
79,152.15
(
0.63%
)
News Focus
News Focus
Post# of 438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1063
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 250

Tuesday, 07/17/2018 9:04:33 AM

Tuesday, July 17, 2018 9:04:33 AM

Post# of 438
ACRX may benefit from legislation that allows DOD to use medical products that are unapproved by the FDA.

Rather than cede control of a group of treatments to another agency, FDA has agreed to expedite development and review of treatments upon Secretary of Defense request.

As a result, DSUVIA is in a much stronger position for approval for its 11/3/18 PDUFA.

Watch for an October Adcom.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today